NCT07138677 · RECRUITING
Safty and Efficacy of MCI Network Guided TMS for Early Alzheimer's Disease: A Randomized, Double-blind Trial
This trial is testing a personalized form of transcranial magnetic stimulation, or TMS, in people with early Alzheimer's disease or mild cognitive impairment due to AD. TMS uses magnetic pulses to stimulate specific brain networks. Researchers are checking whether targeting those networks more precisely improves thinking and memory, and whether it is safe. This is a Phase NA randomized, double-blind trial, meaning it is a controlled experiment but not classified under the standard drug-trial phase system.
You may qualify if
- Subject diagnosed as either mild cognitive impairment due to AD or mild AD dementia based on National Institute on Aging-Alzheimer's Association criteria.
- MMSE score 18-28.
- CDR score 0.5-1.
- On stable treatment with IAChE or memantine for at least 6 months.
- Literate in Han Chinese.
You're excluded if
- Recevied rTMS treatment in the past 3 months.
- Depression or other psychiatric disorders.
- History of head injury, stroke, epilepsy or other neurologic disease.
- Organic brain defects on T1 or T2 images.
- History of unexplained loss of consciousness.
- Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, or any implanted medical device that is incompatible with MRI.
- Family history of medication refractory epilepsy.
- History of substance abuse within the last 6 months.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-09-15